drugset / Trial / NCT05869227
Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma
Phase 3
Active not recruiting
166 enrolled
XIANG YANQUN
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collabZhujiang Hospital · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The aim of this study is to investigate the efficacy and safety of the "capecitabine combined with toripalimab maintenance regimen" in improving the first-line treatment of recurrent and metastatic nasopharyngeal carcinoma after receiving remission through chemotherapy combined with anti PD-1 monoclonal antibody standard regimen.
Timeline
- Start
- 2023-04-28
- Primary completion
- 2027-12-20
- Completion
- 2027-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Background | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |